Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial

By sjmartinez • May 31, 2023

Baksh SN, Heath SL, Fukuta Y, Shade D, Meisenberg B, Bloch EM, Tobian AAR, Spivak ES, Patel B, Gerber J, Raval JS, Forthal D, Paxton J, Mosnaim G, Anjan S, Blair J, Cachay E, Currier J, Das P, Huaman M, Sutcliffe C, Yarava A, Casadevall A, Sullivan D, Hanley D, Gebo KA. Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial. J Infect Dis. 2023 May 29;227(11):1266-1273. doi: 10.1093/infdis/jiad023. PMID: 36722044; PMCID: PMC10226658.

Tags: covid-19, COVID-19 serotherapy, Infectious Diseases, plasma, Publications, Symptom duration

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response

Gu Y, Singh S, Alqarihi A, Alkhazraji S, Gebremariam T, Youssef EG, Liu H, Fan X, Jiang WR, Andes D, Cochrane TR, Schwartz JA, Filler[...]

Leveraging near-real-time patient and population data to incorporate fluctuating risk of severe COVID-19: development and prospective validation of a personalised risk prediction tool

Swinnerton K, Fillmore NR, Vo A, La J, Elbers D, Brophy M, Do NV, Monach PA, Branch-Elliman W. Leveraging near-real-time patient and population data to[...]

Variability of antimicrobial susceptibility of commensal Neisseria species supports its use as a marker of excessive antimicrobial consumption – reflections from the results of a four-country study

Kanesaka I, Foschi C, Marangoni A, Adamson PC, Klausner J, Dong HV, Vanbaelen T, De Baetselier I, de Block T, Manoharan-Basil SS, Kenyon C. Variability[...]